Physician profile
Eric Reish
NPI 1801086202
$23,190.48
in general payments reported to CMS, 2019-2025
33 companies · $2,916 in 2025
The $2,916 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,383 · 2020: $1,256 · 2021: $3,486 · 2022: $3,773 · 2023: $5,063 · 2024: $4,312 · 2025: $2,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,144 · Consulting Fee: $2,925 · Education: $200 · Entertainment: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,143.77 |
| Consulting Fee | $2,925.00 |
| Education | $199.98 |
| Entertainment | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $8,079.70 | 2019-2025 | Lensx, Hydrus Microstent, Argos |
| Glaukos Corporation | $5,682.51 | 2019-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Sight Sciences, INC. | $1,874.90 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Ivantis, INC | $1,757.53 | 2020-2021 | |
| New World Medical,INC. | $1,068.49 | 2021-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Rxsight INC | $716.81 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $598.51 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| Abbvie INC. | $446.79 | 2022-2025 | |
| Allergan, INC. | $411.60 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $390.69 | 2022-2025 | Acthar |
| Biotissue Holdings INC. | $352.70 | 2023-2025 | |
| Aerie Pharmaceuticals, INC. | $300.76 | 2019-2021 | |
| Ocular Therapeutix, INC. | $256.94 | 2022-2025 | Dextenza |
| Genentech USA, INC. | $228.27 | 2023-2025 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $193.57 | 2024-2025 | Xdemvy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $133.55 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $90.94 | 2022-2025 | Omidria, Rayone Aspheric, Rayner Cataract Set 1 |
| Oyster Point Pharma, INC. | $81.66 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $81.41 | 2019-2025 | Oxervate |
| Merz Pharmaceuticals, LLC | $71.36 | 2022 | |
| Apellis Pharmaceuticals, INC. | $66.09 | 2023-2025 | Syfovre |
| Boston Scientific Corporation | $58.48 | 2025 | General - Therapies |
| Bausch & Lomb Americas INC. | $51.81 | 2022-2024 | Envista Mx60 Iol, Vyzulta |
| Biogen, INC. | $36.38 | 2024 | Byooviz |
| Horizon Therapeutics Plc | $35.68 | 2023 | Tepezza |
| Amgen INC. | $33.82 | 2025 | Tepezza |
| Nova Eye, INC. | $22.00 | 2025 | |
| Tearlab Corp | $17.52 | 2019 | |
| Harrow Eye, LLC | $14.62 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $12.42 | 2020 | |
| Eyevance Pharmaceuticals LLC | $11.98 | 2019 | |
| Omeros Corporation | $10.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Reish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.